US Bancorp DE raised its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 22.3% during the fourth quarter, ...

BofA resumed coverage of Sage Therapeutics (SAGE) with an Underperform rating and $5 price target. The impact of Biogen’s (BIIB) unsolicited ...

A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have added about 7.4% in that time frame, outperforming the S&P 500. Will the recent positive trend ...

Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Equities research analysts forecast that Sage Therapeutics will post -3.52 EPS for the current ...

JPMorgan analyst Anupam Rama established a $9 December 2025 price target on shares of Sage Therapeutics (SAGE) while keeping a Neutral rating ...

In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against other best small-cap growth stocks to buy now. On November 4, 2024, Nick Sheridan ...

As the Cambridge drugmaker contemplates its future, the biotech’s chief medical officer has become the latest executive to exit the company. As Sage Therapeutics Inc. contemplates its path ...

Sage Therapeutics, Inc. (NASDAQ: SAGE) announced that partner Biogen (NASDAQ: BIIB) has terminated its rights related to the investigational neurology candidate, SAGE-324.